Collegium Pharmaceutical Enters $50 Million Accelerated Share Repurchase Agreement

MT Newswires Live08-13

Collegium Pharmaceutical (COLL) said Thursday it has entered into an accelerated share repurchase agreement with Jefferies to repurchase $50 million of its common stock as part of the $150 million program authorized by its board in July 2025.

Under the terms of the agreement, Collegium will pay $50 million to Jefferies for an initial delivery of 1,556,420 shares, representing around 80% of the shares it expects to buy back, according to a statement. The initial delivery is based on Collegium's $25.70 closing share price on Aug. 12.

The final settlement of the agreement is expected to be completed no later than the fourth quarter of 2026, the company said. Upon completion of the ASR, Collegium will have $100 million remaining under its board-authorized repurchase program.

Collegium said it had about 32.5 million shares outstanding as of June 30.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2659815770?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 21:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2659815770","market":"us","top_or_hot":-1,"title":"Collegium Pharmaceutical Enters $50 Million Accelerated Share Repurchase Agreement","media":"MT Newswires Live","content":"<html><body><p> Collegium Pharmaceutical (COLL) said Thursday it has entered into an accelerated share repurchase agreement with Jefferies to repurchase $50 million of its common stock as part of the $150 million program authorized by its board in July 2025.</p><p>Under the terms of the agreement, Collegium will pay $50 million to Jefferies for an initial delivery of 1,556,420 shares, representing around 80% of the shares it expects to buy back, according to a statement. The initial delivery is based on Collegium's $25.70 closing share price on Aug. 12.</p><p>The final settlement of the agreement is expected to be completed no later than the fourth quarter of 2026, the company said. Upon completion of the ASR, Collegium will have $100 million remaining under its board-authorized repurchase program.</p><p>Collegium said it had about 32.5 million shares outstanding as of June 30.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Collegium Pharmaceutical Enters $50 Million Accelerated Share Repurchase Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCollegium Pharmaceutical Enters $50 Million Accelerated Share Repurchase Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-13 21:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Collegium Pharmaceutical (COLL) said Thursday it has entered into an accelerated share repurchase agreement with Jefferies to repurchase $50 million of its common stock as part of the $150 million program authorized by its board in July 2025.</p><p>Under the terms of the agreement, Collegium will pay $50 million to Jefferies for an initial delivery of 1,556,420 shares, representing around 80% of the shares it expects to buy back, according to a statement. The initial delivery is based on Collegium's $25.70 closing share price on Aug. 12.</p><p>The final settlement of the agreement is expected to be completed no later than the fourth quarter of 2026, the company said. Upon completion of the ASR, Collegium will have $100 million remaining under its board-authorized repurchase program.</p><p>Collegium said it had about 32.5 million shares outstanding as of June 30.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"COLL","symbol_name":"Collegium Pharmaceutical, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2659815770","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2659815770","pubTimestamp":1786627185,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Collegium Pharmaceutical  said Thursday it has entered into an accelerated share repurchase agreement with Jefferies to repurchase $50 million of its common stock as part of the $150 million program authorized by its board in July 2025.Under the terms of the agreement, Collegium will pay $50 million to Jefferies for an initial delivery of 1,556,420 shares, representing around 80% of the shares it expects to buy back, according to a statement. The initial delivery is based on Collegium's $25.70 closing share price on Aug. 12.The final settlement of the agreement is expected to be completed no later than the fourth quarter of 2026, the company said. Upon completion of the ASR, Collegium will have $100 million remaining under its board-authorized repurchase program.Collegium said it had about 32.5 million shares outstanding as of June 30.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"COLL":"Collegium Pharmaceutical, Inc.","BK4007":"制药"},"translate_title":"Collegium Pharmaceutical 签订 5000 万美元加速股票回购协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COLL":1.5},"content_text":"Collegium Pharmaceutical (COLL) said Thursday it has entered into an accelerated share repurchase agreement with Jefferies to repurchase $50 million of its common stock as part of the $150 million program authorized by its board in July 2025.Under the terms of the agreement, Collegium will pay $50 million to Jefferies for an initial delivery of 1,556,420 shares, representing around 80% of the shares it expects to buy back, according to a statement. The initial delivery is based on Collegium's $25.70 closing share price on Aug. 12.The final settlement of the agreement is expected to be completed no later than the fourth quarter of 2026, the company said. Upon completion of the ASR, Collegium will have $100 million remaining under its board-authorized repurchase program.Collegium said it had about 32.5 million shares outstanding as of June 30.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2659815770","isCrawlerRequest":true}